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ABSTRACT
MicroRNAs, small non-coding RNAs, may act as tumor
suppressors or oncogenes, and each regulate their own
transcription and that of hundreds of genes, often in
a tissue-dependent manner. This creates a tightly
interwoven network regulating and underlying
oncogenesis and cancer biology. Although protein-coding
gene signatures and single protein pathway markers
have proliferated over the past decade, routine adoption
of the former has been hampered by interpretability,
reproducibility, and dimensionality, whereas the single
moleculeephenotype reductionism of the latter is often
overly simplistic to account for complex phenotypes.
MicroRNA-derived biomarkers offer a powerful
alternative; they have both the ﬂexibility of gene
expression signature classiﬁers and the desirable
mechanistic transparency of single protein biomarkers.
Furthermore, several advances have recently
demonstrated the robust detection of microRNAs from
various bioﬂuids, thus providing an additional opportunity
for obtaining bioinformatically derived biomarkers to
accelerate the identiﬁcation of individual patients for
personalized therapy.
OVERVIEW OF MICRORNAS, CLASSIFICATION,
BIOLOGY, AND ROLE IN CANCER
Since the awarding of the 2006 Nobel Prize in
Medicine to the discoverers of microRNAs
(miRNAs),
1 there has been an enhanced interest in
these molecules and an explosion of data. miRNAs
are 19e24 nucleotides in length, and to date 1424
human mature and immature forms have been
cataloged (http://www.mirbase.org).
2 They are
omnipresent, stable, and increasingly recognized as
critical modulators of biological, in particular
oncogenic, pathways. They are often tissue
speciﬁc
3 and developmental stage speciﬁc.
4
miRNAs participate in RNA interference (RNAi)
pathways, which affect the level of expression of
mRNA transcripts. miRNAs, which have multiple
targets in contrast with other RNAi molecules such
as small interfering RNAs (siRNAs), induce degra-
dation of speciﬁc mRNAs by bearing fully homol-
ogous target sites.
5 miRNAs are located in fragile
chromosome areas prone to deletions, ampliﬁca-
tions, and translocations.
6 They interact with their
target mRNAs in multiple ways, and, although
they only represent 1% of the human genome, it
has been estimated that at least a third of the
genome is probably regulated by miRNAs.
7 Addi-
tionally, 60% of their 39 untranslated region (UTR)
target sites are evolutionary conserved, suggesting
an equally conserved role for miRNAs.
8 Most
miRNAs are derived from precursor RNA and
function by base pairing with their target mRNAs
to modulate protein translation by directly
preventing either mRNA repression or degradation
typically through 39 UTR binding. However,
multiple other mechanisms have been biologically
described and insufﬁciently bioinformatically
modeled in an excellent review by Garzon et al
9:
they include binding to the 59 UTR or the open
reading frame or in fact activating, instead of
repressing, translation. One miRNA can target up
to 500 mRNAs, and multiple mRNAs can be
targeted by multiple miRNAs.
Although miRNAs only modestly inhibit gene
expression, they preferentially target hubs and
bottleneck proteins, which ampliﬁes their regula-
tory impact on dynamic protein networks.
10 In
oncology, some tumor suppressor miRNAs target
multiple oncogenes,
10 whereas others have been
reported to be deleted in leukemia and subsequently
found to be altered in multiple cancers.
6 In fact,
miRNA expression patterns have been demon-
strated to have superior accuracy for classifying
tumors of unknown origin compared with mRNA-
based patterns.
3 They have been shown to initiate
carcinogenesis (so-called “oncomirs”) or drive
progression of disease. Indeed, simply querying
a database predicting miRNA targets using
sequence alignment of miRNA and mRNAwith the
keyword “cancer” will return w20% of available
human miRNAs.
2 To put this in perspective, only
w1% of the protein-coding genome has been
directly implicated in cancer
11; therefore, miRNAs
are far more enriched for oncogenic pathways than
their mRNA counterparts.
Despite our increased knowledge of the onco-
logical functions of miRNAs and our ability to
assay them, miRNA knowledge translation from
the laboratory bench to the patient bedside has
been limited at best. A simple PubMed search
(performed May 1, 2011) with search terms
“microRNA or miRNA” and “signature” returned
only 310 hits, whereas a similar query using
“mRNA or gene and signature” returned
nearly 7000 entries. In this perspective, we contend
that bioinformatics can and should play an essen-
tial role in bridging this translational gap. In
particular, we explore how: (1) a similar length
signature provides better genomic coverage than
mRNAs; (2) the probability of a statistically and
clinically signiﬁcant ﬁnding is greater than from
conventional mRNA-based results because of
reduced dimensionality; (3) miRNA stability and
ability to be extracted from multiple bioﬂuids
and pre-genomics era tumor banks are a boon to
cancer researchers for validation and training
samples.
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A practical consideration in favor of miRNAs is their stability in
many types of tissue. Old tumor banks consist primarily of
formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue, as this was the
method of choice for preserving tissue morphology. However,
this procedure limits their usage in genomic studies. Formalin
ﬁxation causes cross-linking of tissue proteins with one another
and other DNA and RNA molecules. Although the protein
architecture is preserved, nucleic acid extraction is difﬁcult.
Furthermore, an analysis of RNA from FFPE specimens
demonstrated modiﬁcation of the RNA structure, rendering
reverse transcription difﬁcult.
12 Consequently, for mRNA
expression analysis, ﬂash-frozen specimens have been the tissue
of choice.
Fortunately, these limitations are not necessarily relevant for
miRNA. miRNA extracted from FFPE specimens even after
10 years showed similar expression patterns to ﬂash-frozen
tissue.
13 Even laser dissection of tumor from FFPE blocks after
immunohistostaining has generated robust miRNA expression
patterns.
13 14 Further, miRNA quality does not correlate with
RNA quality as assayed by capillary electrophoresis. Thus, tissue
banks of FFPE specimens previously thought to be of insufﬁcient
quality for genomic proﬁling may be a treasure trove for high-
throughput miRNA transcriptome proﬁling and subsequent
bioinformatics analysis.
Equally exciting is the discovery that, unlike mRNAs which
are rapidly degraded, miRNAs are not only found in tissue, but
are ubiquitously found in all body ﬂuids, including blood, urine,
and saliva.
15 In the future, miRNA bioﬂuid proﬁling may
become the de facto non-invasive standard for evaluating tumor
status. Indeed, the ﬁrst paper on plasma-based miRNAs
demonstrated its ability to differentiate patients with prostate
cancer from those who did not.
16 Furthermore, it was recently
demonstrated that blood-based miRNAs from historic tumor/
blood banks could predict lung cancer recurrence 1e2 years
before radiographic detection
17 with similar prognostic abilities
demonstrated in colon cancer.
18 However, the concordance
between plasma and tissue miRNAs may be poor.
17 These
plasma/serum biomarkers may be indicative of cellular processes
that are not cancer-related, and thus identifying bioﬂuid-based
miRNAs that are tumor speciﬁc will be critical to proper
interpretation.
BIOMARKER CHALLENGES IN CANCER
Cancer is an extremely heterogeneous disease. Not only does the
derivative tissue (eg, breast, prostate) matter, but the origin of
the transformed cells also has tremendous importance in tumor
behavior and prognosis. There are multiple publications
demonstrating that miRNA biomarkers are associated with
these transformed cell subtypes. In breast cancer, miRNAs can
classify estrogen receptor, progesterone receptor, and HER2/neu
status, which are critical for treatment-related decisions.
19 For
a given cell of origin, the genetic alterations conferring its
malignant phenotype are equally diverse. Epigenetic silencing,
gene mutations, ampliﬁcations, and deletions are but a few of
the modalities that alter the molecular pathways. Fortunately,
miRNAs, too, are effective in predicting mutational status. Work
by the Croce laboratory demonstrated that miRNA expression
patterns could classify translocation-speciﬁc subtypes of
multiple myeloma.
20
As a general rule, tumors adapt to treatment (eg, chemo-
therapy) pressure and will select clonal variations of the tumor
that have different activated pathways. For example, in
biochemically recurrent prostate cancer, hormone therapy is
effective in 80e90% of men; however, most men will have
transcriptome changes and become resistant to this therapy in
1e2 years.
21 Even assuming that one has somehow managed to
select the proper medication for the patient, germ-line differ-
ences may affect drug metabolism and thus drug efﬁcacy. By
deﬁnition, a biomarker is a measured quality that is an indicator
of normal biologic processes, pathogenic processes, or pharma-
cologic responses.
22 Achieving the goal of personalized medicine
will require a multitude of biomarkers constantly capturing the
changing state of the patient and the tumor.
As miRNAs are part of the transcriptome, they provide
chronological snapshots of the transcriptome. In contrast, static
germ-like markers, such as germ-line single-nucleotide poly-
morphisms, are not reﬂective of the current disease state, and
thus their association or correlation with therapeutically
important disease characteristics is likely to be more indirect.
miRNAs are often biologically interpretable and may offer causal
relationships to aspects of the somatic transcriptome that can be
targeted by therapy.
BIOINFORMATICS CONSIDERATIONS IN REDUCING THE
DIMENSIONALITY OF HETEROGENEOUS EXPRESSION PROFILES
By deﬁnition, a transcriptome signature is a classiﬁer that
provides identiﬁcation of a class of tumor (eg, good vs poor risk)
based on the expression levels of the component mRNA or
miRNA. In most cases, these signatures are derived by exam-
ining the differential expression of the transcriptome from
discrete cancer states. In our experience, there may be upwards
of 500e1000 signiﬁcantly differentially expressed genes in each
phenotypic comparison, constituting w4% (1000 of 25000
transcripts) of the genome surveyed. For either technical or cost
reasons, most researchers will eventually winnow down this list
to a smaller set of 10e100 features (genes) by pruning among co-
expressed groups of genes. This approach may well prioritize
bystander or passenger genes rather than the co-expressed genes
driving the oncogenesis. This said, these smaller signatures are
really now only evaluating 0.2e0.4% of the mRNA tran-
scriptome. As this reduction in dimensionality is generally
performed with supervised learning algorithms on oftentimes
limited datasets, these smaller feature sets can become unstable
(their membership may change with repeated analysis), become
less informative, or, more likely, become overﬁtted to the
training data.
23 Multiple researchers have demonstrated that
short gene signatures are inherently unstable, and repeated
permutations will choose different genes and are prone to
making random associations.
24 25 Further, gene expression
signature classiﬁers have been shown to have poor overlap when
developed independently in distinct datasets.
26
With miRNA expression signatures, the typical length is
between 15 and 100 features without the need for extensive
post-processing. Although this signature length may seem
comparable to the length of mRNA signatures mentioned above,
there is a fundamental difference. The miRNA space is consid-
erably smaller, and, at these gene signature lengths, there is
coverage of up to 10% of the genomic space (100 out of w1000
mature miRNAs). Simply put, for a similarly sized signature,
miRNA signatures provide better coverage and the increased
probability of statistically more informative features.
As of the writing of this perspective, the cost to process an
mRNA microarray for the entire human genome is equivalent to
higher-quality real time-PCR (RT-PCR) based technology for
proﬁling all known miRNAs. RT-PCR technology remains the
gold standard for expression proﬁling because of its superior
detection sensitivity, superior assay speciﬁcity, and wider linear
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27 28 Indeed, microarray expression data varied by
as much as 60% when compared with RT-PCR-derived data.
28
Therefore, for a similar cost, RT-PCR-derived differentially
expressed miRNAs are more likely to be accurate with lower
variance than their microarray mRNA counterparts. In other
words, miRNA measures are both highly accurate and highly
precise (reproducibility), while expression arrays yield mRNA
measures with less precision (high variance on repeated
measures). Therefore, even before statistical analysis is
performed, miRNA proﬁling may provide a more reliable signal
than mRNA via microarray.
What is often overlooked in the clinical literature regarding
genomic signatures is that the statistical power for detecting
differentially expressed features (miRNA or mRNA) is depen-
dent on the genomic space that is being evaluated. Given a set of
m features from an independently developed classiﬁer, assume
m0 are the differentially expressed features between paired
samples in a validation dataset. Let m1 be the non-differentially
expressed features. The number of classiﬁer features that are
declared differentially expressed (true positive (TP)) divided by
the sum of TP and the number of differentially expressed
features represents the sensitivity (TP/(TP+m1)). Similarly, TN/
(TN+m0) represents the speciﬁcity where the true negative
(TN) is the number of true null hypotheses correctly identiﬁed
by the classiﬁer. Thus, on the basis of this simple math, we can
see that, in large transcriptome proﬁling data, the greater the
number of features proﬁled, the lower the sensitivity and
speciﬁcity and the greater the number of samples required.
This problem of dimensionality carries over to corrections for
multiplicity. Inherently, with the greater number of features,
there is a greater risk of a random false positive. Several methods
have been developed to address this. For example, the popular
Benjamini and Hochberg
29 FDR approach controls this proba-
bility by ﬁnding a comparison-wise error level such that the
error is proportional to the number of signiﬁcant features and
the desired overall p value from the observed dataset. More
concretely, let us take, for example, differentially expressed genes
from a paired microarray experiment. Assume that we would
like to have an overall t test p value of 0.05 adjusted for multiple
comparisons to derive a biomarker from a given feature. We
would like to calculate the threshold for signiﬁcance based on
a straightforward Bonferroni-type correction.
30 This consists of
multiplying the unadjusted p value by the total number of
features evaluated to obtain an adjusted p value. Comparing
20000 mRNA features with 1000 miRNA features, there is a 20-
fold difference in the adjusted p value: an unadjusted p value of
0.00001 becomes adjusted-pmRNA¼1 (not signiﬁcant), while
adjusted-pmiRNA¼0.01 (signiﬁcant). Therefore, with limited
patient samples, a previously underpowered study in the mRNA
space may now be statistically feasible in the miRNA space.
BIOINFORMATICS-DERIVED MIRNA CLASSIFIERS ANCHORED
IN BIOLOGICAL MECHANISMS: OPPORTUNITIES AND
CHALLENGES
miRNA-based biomarkers are currently limited by the scale of
the number of interactions and thus offer a unique modeling
challenge that lends them to computational analysis. The power
of miRNAs lies in their stunning array of functions and poten-
tial targets and deep inﬁltration of critical pathways. A subtle
change in miRNA expression has potentially far-reaching effects
on cellular signaling. However, if identifying key protein coding
mRNAs is the ultimate research goal, miRNA targeting multi-
plicity would be disadvantageous. If one is interested in the
miRNAs themselves (sometimes described as non-coding genes
or non-coding RNA), the advantage is certain. Nevertheless, in
comparison with mRNA-based expression signature classiﬁers,
changes in miRNA expression have a greater chance of being
biologically relevant. Unlike traditional protein-based regulatory
pathways where each mRNA-coding protein is constrained to
usually no more than one or two regulatory pathways, the
miRNA regulatory network exists in multidimensional space.
While straightforward statistics can control for the set of
potential interactions, these unsupervised approaches are
generally insufﬁcient to reach statistical signiﬁcance and are not
designed to unveil the underpinning molecular mechanisms.
Indeed, each miRNA exponentially increases the network
complexity, as they exist in a many-to-many relationship, with
multiple miRNAs regulating target genes in a potentially over-
lapping manner. Second, each mRNAemiRNA interaction is
speciﬁc to the cell-type context and does not necessarily result in
a uniform, consistently predictable outcome.
3
However, miRNAs are non-protein-coding genes and thus
cannot be appraised by pathologists using the common immu-
nohistochemistry approach. A plethora of biological functions
can be assigned to each miRNA via its hundreds of gene targets.
Part of the challenge that we and other researchers have
attempted to address in the protein-coding mRNA space is to
develop a computational means of identifying the subset of
primary “driver” alterations (alterations that confer a clonal
growth advantage on cancers) or passengers, a byproduct of
a magniﬁed downstream effect in genome-wide mRNA
changes.
31 32 This is a non-trivial task as, for example, even after
examination of over 746 cancer cell lines, fewer than 0.3% were
discovered to be driver mutations.
33 To focus further on these
driver mechanisms, we have used knowledge from multiple
biological domains to further prioritize within the
miRNAemRNA network inferred from expression patterns
10:
sequence alignment between miRNA and its putative mRNA
targets, genetic oncogenes from the Online Mendelian Inheri-
tance in Man,
34 proteineprotein interaction networks, canonical
molecular pathways, and biological mechanisms from Gene
Ontology annotations. While miRNAemRNA sequence align-
ment databases generally report precisions of w30% in identi-
fying any miRNA targets, we conﬁrmed through biological
experiments w85% precision in identifying miRNA targets as
well as its predicted tumor suppressor functions in head and
neck cancer.
10 This study not only uncovered connections
between miRNA regulation, protein network topology, and
expression dynamics, but also demonstrated a workﬂow for
translating an in silico miRNA-regulated network into
biomarker development in clinical trials.
Other bioinformatics approaches have focused on imputing
the miRNAemRNA, miRNAemiRNA, and miRNAepathway
networks.
2 10 35e37 Although useful, existing algorithms for
scoring or imputing miRNAemRNA interactions only calculate
probability of downregulation of the target mRNA transcript
protein. These network models of miRNA interactions lack
clinical translation and resolution to clinically meaningful
biomarkers. Additionally, the computational modeling of
miRNA-related mechanisms merits attention. For example, to
our knowledge, there are no provisions for considering the
recently discovered upregulation of mRNA expression with
increased miRNA expression
9 and interactions between epige-
netic and miRNA regulation of mRNA expression. Indeed,
miRNA transcription can be regulated by both methylation and
direct methylation of target sites.
38 39 New opportunities arise
from new molecular measurements such as (1) modeling post-
transcriptional regulation using multiplexing measures of
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40 and improved
MS,
41 or (2) discovering individualized regulatory patterns using
high-throughput sequencing of DNA or RNA. While high-
throughput sequencing databases of miRNA regulatory regions
of mRNA transcripts are emerging and may reveal clinically
informative patterns,
42 combined mRNA/miRNA transcription
proﬁles are only interpretable in the context of full integration
with clinical phenotyping data, an exercise that exceeds the
storage and computing requirements of standard computing
approaches and may require computation in GRID or CLOUD
space.
43 As pharmacogenetic knowledge of common variants
was informative for imputing the pathophysiology of rare
variants,
44 so too will the knowledge of miRNAemRNA regu-
latory networks.
Perhaps an even greater bioinformatics opportunity is inte-
grating phenotypic or domain knowledge into these miRNA
networks. Incorporating this additional information will be
essential to improve the accuracy of predictions.
45 Indeed, taken
together, miRNA modeling is clearly at its nascence. Indeed,
there are no bioﬂuid-based miRNA networks. More robust,
domain-constrained, multi-scale informatics models will be
essential to properly identify miRNAs and their targets in an
efﬁcient, unbiased manner for the personalization of medicine.
Figure 1 provides a summary of the advantages of miRNA
signatures compared with mRNA signatures.
CONCLUSION
Taken together, bioinformatics has an outstanding opportunity
to accelerate the development of miRNA-based biomarkers in
cancer for the personalization of medicine. Although miRNA-
based biomarkers have the advantages of manageable dimen-
sionality, ease of testing, and clinical import, they are ultimately
hampered by the sheer complexity of their interactions. Without
doubt, computational models, currently underdeveloped, are
desirable and high impact. Indeed, we ﬁrmly hold that network
models will ultimately function as the critical bridge between
miRNA tumor biology and the individualized care of cancer
patients.
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